Cargando…
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
Chronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general population. Approximately one-third of patients are candidates for systemic immunosuppressive treatments, such as synthetic or biological disease-modifying antirheumatic drugs, because of disease extensions, local...
Autores principales: | Gisondi, Paolo, Bellinato, Francesco, Chiricozzi, Andrea, Girolomoni, Giampiero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761600/ https://www.ncbi.nlm.nih.gov/pubmed/33276686 http://dx.doi.org/10.3390/vaccines8040728 |
Ejemplares similares
-
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
por: Chiricozzi, Andrea, et al.
Publicado: (2020) -
Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020) -
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016) -
Central Pain Sensitization in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2023)